Cefizoxime: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
ClaireLewis (talk | contribs) No edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: 3rd generation [[cephalosporin]] (Discontinued) | ||
*Dosage Forms: | *Dosage Forms: powder for injection | ||
*Common Trade Names: | *Dosage Strengths: 500mg, 1g, 2g, 10g | ||
*Routes of Administration: IV, IM | |||
*Common Trade Names: Cefizox | |||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 27: | Line 29: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 1.6 - 1.9/hr | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: urine, as unchanged drug | ||
*Mechanism of Action: | *Mechanism of Action: arrests bacterial growth by binding to one or more penicillin binding proteins | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
| Line 158: | Line 160: | ||
==See Also== | ==See Also== | ||
== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] | ||
Latest revision as of 21:50, 19 September 2019
General
- Type: 3rd generation cephalosporin (Discontinued)
- Dosage Forms: powder for injection
- Dosage Strengths: 500mg, 1g, 2g, 10g
- Routes of Administration: IV, IM
- Common Trade Names: Cefizox
Adult Dosing
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 1.6 - 1.9/hr
- Metabolism:
- Excretion: urine, as unchanged drug
- Mechanism of Action: arrests bacterial growth by binding to one or more penicillin binding proteins
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014